Mirion still sees FY24 adjusted EPS 37c-42c, consensus 39c

Mirion (MIR) is updating components of its guidance for the fiscal year and 12-month period ending December 31, 2024: Revenue growth of 6% to 7%, compared to 5% to 7% previously; Organic revenue growth of 5% to 6%, compared to 4% to 6% previously; Medical LSD organic growth, compared to LSD+ previously; Technologies MSD+ organic growth, which is unchanged. Adjusted EBITDA of $195 million to $205 million, which is unchanged; Adjusted free cash flow of $65 million to $75 million, compared to $65 million to $85 million previously.